Compare Bajaj Finserv Healthcare Fund vs SBI Healthcare Opportunities Fund
Bajaj Finserv Healthcare Fund
EquitySectoral-Pharma
SBI Healthcare Opportunities Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹500
Expense Ratio
2.59
1.99
NAV
₹11.47
₹573.88
Fund Started
06 Dec 2024
04 Jun 1999
Fund Size
₹405.14 Cr
₹5870.00 Cr
Exit Load
1% for redemption within 3 Months
Exit load of 0.50% if redeemed within 15 days
1 Year
12.97%
13.24%
3 Year
-
22.46%
5 Year
-
17.06%
Equity
95.56%
95.53%
Cash
2.12%
4.41%
Top 10 Holdings
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 9.75% |
Sun Pharmaceutical Industries Ltd. | 8.96% |
Piramal Pharma Ltd. | 6.36% |
Rubicon Research Ltd. | 6.08% |
Aurobindo Pharma Ltd. | 6.03% |
Apollo Hospitals Enterprise Ltd. | 5.51% |
Torrent Pharmaceuticals Ltd. | 4.78% |
Emcure Pharmaceuticals Ltd. | 4.03% |
Laurus Labs Ltd. | 3.91% |
Neuland Laboratories Ltd. | 3.82% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.14% |
Divi's Laboratories Ltd. | 7.91% |
Acutaas Chemicals Ltd. | 5.03% |
Apollo Hospitals Enterprise Ltd. | 4.45% |
Torrent Pharmaceuticals Ltd. | 4.42% |
Cipla Ltd. | 4.40% |
Laurus Labs Ltd. | 4.05% |
Max Healthcare Institute Ltd. | 3.80% |
Aurobindo Pharma Ltd. | 3.42% |
Aster DM Quality Care Ltd. | 3.21% |
Name
-
-
Start Date
-
-
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
06 Dec 2024
04 Jun 1999
